AngioDynamics (ANGO) Beats Q3 Estimates Amid Strong Med Tech Demand

Key Facts

1AngioDynamics (ANGO) exceeded analyst estimates in its fiscal third-quarter results.

2Revenue rose and losses narrowed, driven by strong demand in the Med Tech sector.

3Gross margin experienced a decline despite the beat on revenue and earnings.

AngioDynamics (ANGO) reported fiscal third-quarter results that surpassed analyst expectations for both revenue and earnings. The company's performance was bolstered by robust demand within its Med Tech division, leading to a notable increase in overall revenue. Consequently, AngioDynamics saw its net losses narrow during the period, reflecting improved operational efficiency in key segments. Despite the top and bottom-line beats, the company reported a decline in gross margins, which may weigh on long-term profitability outlooks. Investors reacted positively to the news, driving the stock price higher in pre-market trading sessions. These results underscore the resilience of the medical technology sector and the company's ability to leverage innovation.

Open on chart